Overall rank by patents
#10,122
Across all tracked assignees
USPTO PatentsView assignee record - 31 granted patents across 22 technology areas, active 2015–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A23K (FODDER).
The verdict
Novus holds 31 US patents across 22 technology areas, rank #10,122 of 50,000 tracked assignees.
Novus International, Inc. has been granted 31 US utility patents between 2015 and 2025, placing Novus International, Inc. at rank #10,122 across all assignees tracked by PlainPatent. This portfolio spans 22 distinct Cooperative Patent Classification (CPC) subclasses, averaging 20.0 claims per patent with primary concentration in A23K (FODDER). As a US Corporation, Novus International, Inc. is one of the more focused assignees in the PatentsView dataset. By volume, Novus sits between Newleaf Symbiotics, Inc. (31 patents, rank #10,118) and Organovo, Inc. (31 patents, rank #10,126) - the closest US assignees by grant volume. The composite Innovation Score of 41.9/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Between 2020 and 2025 the company received 7 grants, compared with 24 in the 2015–2019 window, a -71% shift in five-year velocity. A cooling filing rate may reflect portfolio consolidation, shifting priorities, or reduced R&D throughput. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. Novus International, Inc.'s 20.0 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while a multi-domain presence across 22 subclasses balances depth with breadth. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Novus International, Inc. against peers pursuing similar technology classes.
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
NewLeaf Symbiotics, Inc.
31 patents
Nordco Inc.
31 patents
Norton Healthcare Limited
31 patents
Novo Nordisk Health Care AG
31 patents
Nytell Software LLC
31 patents
OCTAPHARMA AG
31 patents
OCV Intellectual Capital, LLC
31 patents
ORGANOVO, INC.
31 patents
Novus International, Inc.
31 patents
What this shows Novus holds 31 patents at rank #10,122, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
By rank, the assignees closest to #10,122 in granted patent volume.
Other assignees with the most granted patents in Novus's primary technology class.
Novus's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
42 Top 32% higher than 68% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2015 | 5 | 16.1% |
| 2016 | 5 | 16.1% |
| 2017 | 4 | 12.9% |
| 2018 | 4 | 12.9% |
| 2019 | 6 | 19.4% |
| 2020 | 3 | 9.7% |
| 2021 | 1 | 3.2% |
| 2022 | 1 | 3.2% |
| 2023 | 1 | 3.2% |
| 2025 | 1 | 3.2% |
Top 15 of 22 technology areas
Overall rank by patents
#10,122
Across all tracked assignees
41.9 out of 100
How to use this portfolio
Novus's 31 grants land it in the top 32% by Innovation Score, but volume alone doesn't tell you where the strength sits.
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.